Cigna vs Cvs Health
CI and CVS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CI and CVS compare
Cvs Health is the larger company, worth 1.5 times as much as Cigna ($115B against $78.8B).
Cigna grew revenue faster over the last twelve months (7.8% versus 7.4% for Cvs Health).
Both pay dividends: Cigna yields 2.1% and Cvs Health 2.2%.
Cvs Health scores higher on the StockData Score (12 against 8 for Cigna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CI | CVS |
|---|---|---|
| Size and price | ||
| Market cap | $78.8B | $115B |
| Share price | $298.23 | $90.25 |
| Change, 1 year | −0.30% | 12.0% |
| Change, 5 years | 39.3% | −3.8% |
| Beta (5Y) | 0.33 | 0.47 |
| Employees | 68K | 300K |
| StockData Score | ||
| Total score | 8 | 12 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 2 | 2 |
| Dividend score | 2 | 4 (better) |
| Valuation | ||
| P/E | – | 23.9× |
| P/S | 0.3× | 0.3× (better) |
| P/B | 1.8× | 1.4× (better) |
| EV/EBITDA | 8.2× (better) | 12.7× |
| P/FCF | – | 9.8× |
| FCF yield | – | 10.2% |
| Fair value | – | $77.92 |
| Margin of safety | – | −15.8% |
| Growth | ||
| Revenue growth (TTM) | 7.8% (better) | 7.4% |
| Revenue growth, 5Y average | 11.4% (better) | 8.4% |
| Net income growth (TTM) | – | 7.9% |
| EPS growth (TTM) | – | 5.3% |
| EPS growth, 5Y average | −0.69% (better) | −23.9% |
| Profitability | ||
| Gross margin | 20.6% | 44.5% (better) |
| Operating margin | 3.5% (better) | 2.0% |
| Net margin | – | 1.2% |
| FCF margin | – | 2.8% |
| Return on equity | – | 6.2% |
| Return on invested capital | 12.1% (better) | 5.5% |
| Financial health | ||
| Debt / equity | 0.75 (better) | 0.77 |
| Net debt / EBITDA | 1.94 (better) | 3.70 |
| Interest coverage | 7.2× (better) | 2.7× |
| Current ratio | 0.85 | 0.87 (better) |
| Altman Z-score | 2.80 (better) | 2.45 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | 2.2% (better) |
| Payout ratio | – | 69.9% |
| Years of dividend growth | 5 (better) | 0 |
| Dividend growth, 5Y average | 173% (better) | 5.9% |
| Buyback yield | 1.3% | – |
| Shareholder yield | 3.4% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 89.9% | 89.2% |
| Held by insiders | 0.41% | 0.43% |
| Insider net buying, 12 months | −$65.8M (better) | −$324M |
| Superinvestors holding | 4 | 6 (better) |
| Short interest, % of float | 2.6% | 1.3% |
Go deeper
- CI stock overview
- CI income statement
- CI valuation and score
- CVS stock overview
- CVS income statement
- CVS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.